Ensysce Biosciences, Inc.
ENSC
$0.47
$0.000.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -15.10% | -27.19% | 44.38% | -85.58% | 654.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.10% | -27.19% | 44.38% | -85.58% | 654.35% |
| Cost of Revenue | 28.51% | 77.51% | -4.99% | 74.77% | 103.06% |
| Gross Profit | -136.85% | -321.69% | 30.74% | -242.45% | 27.88% |
| SG&A Expenses | 5.88% | -16.09% | -2.45% | 18.08% | 0.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.82% | 37.60% | -4.42% | 52.63% | 46.08% |
| Operating Income | -47.18% | -81.05% | 22.22% | -680.29% | 10.48% |
| Income Before Tax | -48.31% | -82.79% | 22.34% | -663.48% | 11.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -48.31% | -82.79% | 22.34% | -663.48% | 11.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00% | -- | -- | -- | -- |
| Net Income | -48.30% | -82.79% | 22.35% | -663.48% | 11.91% |
| EBIT | -47.18% | -81.05% | 22.22% | -680.29% | 10.48% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 74.95% | 62.55% | 74.14% | -228.73% | 76.49% |
| Normalized Basic EPS | 74.95% | 62.55% | 74.14% | -228.74% | 76.49% |
| EPS Diluted | 74.95% | 62.55% | 74.14% | -228.73% | 76.49% |
| Normalized Diluted EPS | 74.95% | 62.55% | 74.14% | -228.74% | 76.49% |
| Average Basic Shares Outstanding | 491.91% | 388.15% | 200.24% | 337.69% | 274.67% |
| Average Diluted Shares Outstanding | 491.91% | 388.15% | 200.24% | 337.69% | 274.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |